Context Therapeutics (CNTX) Total Current Liabilities (2020 - 2026)

Context Therapeutics has disclosed Total Current Liabilities across 7 years of filings, most recently posting $6.5 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $6.5 million, up 243.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.5 million (up 243.88% YoY), and the FY2025 annual result was $8.0 million, up 191.8% from the prior year.
• Total Current Liabilities came in at $6.5 million for Q1 2026 at Context Therapeutics, down from $8.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $8.0 million in Q4 2025 to a low of $1.6 million in Q2 2024.
• The 5-year median for Total Current Liabilities is $3.2 million (2023), against an average of $3.8 million.
• Across the five-year window, Total Current Liabilities plunged 57.3% in 2024 and soared 243.88% in 2026, its largest moves.
• Context Therapeutics' Total Current Liabilities stood at $3.2 million in 2022, then jumped by 30.68% to $4.2 million in 2023, then tumbled by 34.43% to $2.7 million in 2024, then surged by 191.8% to $8.0 million in 2025, then retreated by 18.52% to $6.5 million in 2026.
• The last three Total Current Liabilities figures came in at $6.5 million (Q1 2026), $8.0 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.